FertilityBlend
This article was originally published in The Tan Sheet
Executive Summary
"Nutritional supplementation may provide an attractive alternative or complement to conventional fertility therapy," according to a study published in the April Journal of Reproductive Medicine. The double-blind placebo-controlled study followed thirty women aged 24-46 who had tried unsucessfully to conceive for 6 to 36 months. Women received three capsules of either FertilityBlend or placebo per day for three menstrual cycles. After five months, five of the 15 women in the supplement group were pregnant compared to no pregnancies in the placebo group, Lynn Westphal, MD, Department of Obstetrics & Gynecology, Stanford University, et al. find. Daily Wellness Company's FertilityBlend contains chasteberry, l-arganine. An earlier study evaluating the supplement was announced in 2002 (1"The Tan Sheet" May 20, 2002, In Brief)...
You may also be interested in...
FertilityBlend study
Multi-center trial on Daily Wellness Company's FertilityBlend supplements for women, men will follow 200 couples who have tried for over six months to become pregnant. Three-month trial builds on pilot study of 29 women that resulted in pregnancies for four of 14 women in treatment group, compared with no pregnancies in placebo arm. FertilityBlend for women contains chasteberry, l-arginine; men's product has l-carnitine, ferulic acid to "improve the health of sperm," firm says. Supplement is available nationwide at food, drug outlets, health food stores such as GNC...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.